embecta Announces FDA 510(k) Submission for Insulin Patch Pump
January 09, 2024 06:00 ET
|
Embecta Corp.
embecta has submitted a 510(k) premarket filing to the FDA for a proprietary disposable insulin delivery system.
Integrity Applications Announces Uplisting to Nasdaq Capital Market
December 08, 2021 08:30 ET
|
Integrity Applications, Inc.
Wilmington, DE and Or Yehuda, Israel, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for...
Integrity Applications Announces Uplisting to Nasdaq Capital Market
December 08, 2021 08:30 ET
|
Integrity Applications, Inc.
Wilmington, DE and Or Yehuda, Israel, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for...
Plandaí Biotechnology's Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes
May 18, 2017 09:00 ET
|
Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - May 18, 2017) - Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable...
Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
February 08, 2016 09:00 ET
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - February 08, 2016) - Johnson & Johnson (J&J), like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1...